Extended Data Fig. 9: Dietary serine supplementation mitigates 1-deoxysphingolipid in BKS-db/db liver and skin.
From: Insulin-regulated serine and lipid metabolism drive peripheral neuropathy
a) Body weight time-course in BKS-db/db mice fed with either a control (n = 8) or serine supplemented diet (n = 9) for 8 weeks. b) Fasting (6-h) blood glucose time-course in BKS-db/db fed with either a control (n = 8) or serine supplemented diet (n = 9) for 8 weeks. c) Summed hepatic sphingolipids in BKS-db/db mice fed with either a control or serine supplemented diet for 8 weeks (n = 8 per group). d) Summed paw skin sphingolipids in BKS-db/db mice fed with either a control or serine supplemented diet for 8 weeks (n = 8 per group). e) Levels of sphingomyelin species (SM) in the liver in BKS-db/db mice fed with either a control or serine supplemented diet for 8 weeks (n = 8 per group). f) Levels of sphingomyelin species (SM) in the paw skin in BKS-db/db mice fed with either a control or serine supplemented diet for 8 weeks (n = 8 per group). Data are mean ± standard error of mean (SEM) and were analyzed with a two-way ANOVA with Fisher’s LSD post hoc test (a–b) and a two-sided independent t-test (c–f). Statistical analyses in e-f were performed using summed abundances.
